A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy.

ABSTRACT:

Background

Relugolix is the newest form of androgen deprivation therapy (ADT) approved for prostate cancer. However, as an oral drug, several real-world concerns exist, particularly medication compliance, safety with other androgen receptor-targeted agents, and financial burden to patients.

Methods

A single institution retrospective chart review was conducted evaluating all patients who were prescribed relugolix for any prostate cancer indication from January 1, 2021 to January 31, 2022. Demographic data, cardiac risk factors, concomitant therapy usage, and PSA/testosterone levels, were abstracted from the chart review. Adverse effects were obtained by examining progress notes. Compliance was assessed by clinic notes as well as prescription fills by specialty pharmacy record

SUBMITTER: Kasparian S 

PROVIDER: S-EPMC10400130 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature